Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Entrada Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 113 | 1 | 119 | +7 |
| Shares | 24.4M | 1.63M | 25.5M | +2.68M (+11.8%) |
| Value | $251.0M | $16.8M | $321.4M | +$87.3M (+37.3%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Entrada Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 1,256,013 | $15.9M | 0.00% |
| Jones Hill Capital LP | 374,010 | $4.72M | 1.01% |
| Vanguard Portfolio Management LLC | 220,494 | $2.78M | 0.00% |
| Longaeva Partners L.P. | 204,978 | $2.59M | 0.12% |
| Nantahala Capital Management, LLC | 159,332 | $2.01M | 0.13% |
| Vanguard Fiduciary Trust Co | 156,861 | $1.98M | 0.00% |
| Acuta Capital Partners, LLC | 89,358 | $1.13M | 0.80% |
| ADAR1 Capital Management, LLC | 30,500 | $384.9K | 0.02% |
| Shay Capital LLC | 21,548 | $271.9K | 0.04% |
| Vanguard Global Advisers, LLC | 18,398 | $232.2K | 0.00% |
| Harbor Capital Advisors, Inc. | 18,175 | $229.0K | 0.02% |
| Franklin Resources Inc | 11,102 | $140.1K | 0.00% |
| Allworth Financial LP | 309 | $3.90K | 0.00% |
| US Bancorp | 70 | $883 | 0.00% |
| MAI Capital Management | 54 | $682 | 0.00% |
| Wealth Preservation Advisors, LLC | 22 | $278 | 0.00% |
| Farther Finance Advisors, LLC | 17 | $229 | 0.00% |
| Quadrant Capital Group LLC | 18 | $228 | 0.00% |
| SJS Investment Consulting Inc. | 2 | $26 | 0.00% |
| IFP Advisors, Inc | 1 | $13 | 0.00% |
Sold out (13)
Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Algert Global LLC | 128,611 | $1.32M |
| Sphera Funds Management Ltd. | 110,942 | $1.14M |
| Los Angeles Capital Management LLC | 45,952 | $317.1K |
| Point72 Asset Management, L.P. | 21,871 | $224.8K |
| Quest Partners LLC | 15,629 | $160.7K |
| Balyasny Asset Management LLC | 14,017 | $144.1K |
| Walleye Capital LLC | 13,534 | $139.1K |
| Magnetar Financial LLC | 13,373 | $137.5K |
| Intech Investment Management LLC | 11,929 | $122.6K |
| Axq Capital, LP | 10,650 | $109.5K |
| Amalgamated Bank | 894 | $9.00K |
| Daiwa Securities Group Inc. | 150 | $2.00K |
| Covestor Ltd | 99 | $1.00K |
Not filed for Q1 2026 yet (1)
Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 1,632,460 | $16.8M |